Enfortumab vedotin targets Nectin-4 on the cell surface; after internalization, MMAE is released and binds β‑tubulin to disrupt microtubules, causing G2/M arrest and apoptosis. β‑tubulin expression alone does not make cells susceptible—killing requires Nectin‑4–mediated delivery of MMAE.